Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIS793 plus gemcitabine + nab-paclitaxel versus placebo plus gemcitabine + nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma
NL-OMON51502Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nisevokitug in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Novartis. Primary endpoints: Recommended phase 3 dose confirmation and Overall survival. Started Jan 2023; status: active, not recruiting.
02
Drugs
nisevokitug
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NL-OMON51502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51502.